1 rich Libsyn https://www.libsyn.com 300 600 A landmark 10-year follow-up of the HOST-EXAM trial published in The Lancet challenges a century-old assumption: aspirin may no longer be the default for lifelong secondary prevention after PCI. &amp;nbsp; Clopidogrel demonstrated a sustained reduction in ischemic and bleeding events (HR 0.86, p=0.005), with benefits that accumulated over time—yet without a mortality difference. &amp;nbsp; The implication is subtle but profound: we may be witnessing the quiet reshaping of antiplatelet strategy. &amp;nbsp; In cardiology, tradition often lingers—but data, eventually, prevails. Dr. RR Baliga's 'Podkast for the Kurious Doc' http://www.MasterMedFacts.com <iframe title="Libsyn Player" style="border: none" src="//html5-player.libsyn.com/embed/episode/id/40730065/height/300/theme/custom/thumbnail/yes/direction/forward/render-playlist/no/custom-color/88AA3C/" height="300" width="600" scrolling="no" allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen></iframe> https://assets.libsyn.com/secure/content/200438510